• Home
  • NEW DAY MEDICINE
  • 1(39)2022
  • 12 -1 (39) 2022 — Z.A. Nuruzova, Sh.R. Aliev, — EVALUATION OF THE EFFICACY OF COMBINED ANTIBIOTICS AGAINST PURULENT BACTERIAL INFECTIONS

12 -1 (39) 2022 — Z.A. Nuruzova, Sh.R. Aliev, — EVALUATION OF THE EFFICACY OF COMBINED ANTIBIOTICS AGAINST PURULENT BACTERIAL INFECTIONS

EVALUATION OF THE EFFICACY OF COMBINED ANTIBIOTICS AGAINST PURULENT BACTERIAL INFECTIONS

Z.A. Nuruzova, Tashkent Medical Academy

Sh.R. Aliev, Tashkent Medical Academy

O.I. Ergashov Tashkent Medical Academy

Resume

The modern acceleration of the production of medical devices and medicines requires a scientific and analytical study of the effectiveness of modern drugs against pathological microorganisms in each geographical region and country. Undoubtedly, behind scientifically based recommendations on the process of influencing pathological microorganisms isolated from patients, knowledge of the degree of impact of these drugs is a key point in the effectiveness of the treatment and prevention of diseases. Due to mutations of microorganisms and the use of various antibiotics without an analytical approach, they often lead to an increase in the resistance of microorganisms to drugs, and this requires scientific approaches in the development of new combined antibiotics.

Therefore, the effectiveness of combined antibiotics in purulent bacterial infections was analyzed at the Department of Microbiology of the Tashkent Medical Academy, which is one of the leading medical research institutes of the republic. In our study, the main scientific goal was to develop recommendations based on an analytical study to recommend a clinically sound choice of new combined antibacterial substances that have passed clinical trials.

Key words: analysis of the clinical efficacy of therapeutic agents in purulent bacterial infections, antibiotic resistance, clinical bacterial strain, development of analytical recommendations.

First page

58

Last page

64

For citation: Z.A. Nuruzova, Sh.R. Aliev, O.I. Ergashov EVALUATION OF THE EFFICACY OF COMBINED ANTIBIOTICS AGAINST PURULENT BACTERIAL INFECTIONS //New Day in Medicine 1(39)2022 58-64 https://cutt.ly/FIczz9W

LIST OF REFERENCES:

  1. VOZ. Novyye antibiotiki ne reshayut problemu rezistentnosti. // 15.04.2021
  2. VOZ. Ustoychivost’ k antibiotikam. // 21.08.2020
  3. Golub A.V., Kozlov R.S.Tseftolozan/tazobaktam – novyy igrok na pole bor’by s polirezistentnymi vozbuditelyami.//klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. //2018, Tom 20 №4 st. 354-361.
  4. Demikhovskaya Ye. V. MRSA — znamenityy i neizvestnyy Metitsillin- rezistentnyy S.aureus: mekhanizmy rezistentnosti, laboratornaya diagnostika, klinika i epidemiologiya //Bolezni i antibiotiki. 2012. № 2 (7).
  5. 5Ye.Yu. D’yakonova, N.V. Loban’ i dr. Antibakterial’naya profilaktika infektsionnykh oslozhneniy v praktike detskogo khirurga. //V praktiku pediatra, st. 481-484, 06.07.2015.
  6. Zubkov M.N. Sbor, transportirovka biologicheskogo materiala i traktovka rezul’tatov mikrobiologicheskikh issledovaniy. //KMAKH. -2004. –T.6. – №2. – S. 143-154.
  7. Iskhakova Kh.I., Nuruzova Z.A., Vakhidova Kh.V., Shadmanova N.A. Metodicheskiye rekomendatsii «Opredeleniye rodovoy i vidovoy prinadlezhnosti uslovno-patogennykh enterobakteriy, vyyavlennykh pri gnoyno-vospalitel’nykh zabolevaniy i ostrykh kishechnykh infektsiyakh» // –T. -2002. -14 s.
  8. Levchuk I.P., Kostyuchenko M.V. Antibakterial’nyye preparaty dlya mestnoy terapii raneniy razlichnoy etiologii. //RMZH «Meditsinskoye obozreniye» №2(II) ot 28.05.2018 str. 64-68
  9. Mukhamedov I.M., Khuzhayeva SH.A., Khodiyev KH.A. Muzey va klinik shtamm mikroorganizmlarning zamonaviy antibiotiklarga sezgirligi. // Tibbiyotda yangi kun, 2013 4(4), st. 23-26
  10. Armstrong E.S., Farrell D.J., Palchak M., et al. In vitro activity of ceftolozane-tazobactam against anaerobic organisms identified during the ASPECT-cIAI Study. //Antimicrob Agents Chemother. 2016; 666-668.
  11. Bergey’s Manual of Sistematic Bacteriology.-V.2.The Proteobacteria -Springer. 2nd Ed. -2005. 1388p.
  12. Drawz S.M., Bonomo R.A. Three decades of beta-lactamase inhibitors. //Clin Microbiol Rev. 2010; 23:160-201.
  13. Sader H.S., Rhomberg P.R., Farrell D.J., et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. //Antimicrob Agents Chemother. 2011; 55:2390-2394.

file

download